Clinical trials: Pneumonia
Long COVID, Chronic Fatigue Syndrome
Vagus Nerve Stimulation as Treatment for Long Covid
Many patients do not recover following Covid infection. The resulting illness is called Long Covid. Because there is no agreed upon treatment for this ailment, the research team has decided to do an open label pilot study using…
- Trial name
- NCT05608629
- Testing
- Transcutaneous Non-Invasive Vagus Nerve Stimulation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Aspiration, Aspiration Pneumonia
Early Antibiotics After Aspiration in ICU Patients
The purpose of this study is to evaluate the use of early antibiotics in ICU patients who appear to have aspirated, to help determine whether this improves outcomes by reducing the later incidence of pneumonia and other negative…
- Trial name
- NCT05079620
- Testing
- Ceftriaxone, Amoxicillin clavulanic acid, Cefepime
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UConn Health
COVID-19
Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
The primary hypothesis to be tested is whether or not there is a difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo.
- Trial name
- NCT05011513
- Testing
- PF-07321332, Ritonavir
- Where
- 225 sites in United States, Argentina and 18 more
- Volunteers
- 1,440 people
- Sponsor
- Pfizer
MEDI3902 for Prevention of P. Aeruginosa Pneumonia
Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults
This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study evaluating the safety and tolerability of a single ascending IV dose of MEDI3902 in healthy adult subjects 18 to 60 years of age.
- Trial name
- NCT02255760
- Testing
- MEDI3902 - Dose 1, MEDI3902 - Dose 2, MEDI3902 - Dose 3
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Pneumonia, Pelvic Inflammatory Disease
Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
To collect the efficacy and safety information of Azithromycin IV related to their appropriate use in daily practice
- Trial name
- RESCUE (NCT01671280)
- Testing
- Azithromycin IV
- Volunteers
- 403 people
- Sponsor
- Pfizer
Coronavirus, Acute Respiratory Infection
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease
ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19.
- Conditions
- Coronavirus, Acute Respiratory Infection, SARS-CoV Infection
- Trial name
- ORCHID (NCT04332991)
- Testing
- Hydroxychloroquine
- Where
- 40 sites in United States
- Volunteers
- 479 people
- Sponsor
- Massachusetts General Hospital
COVID-19
Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)
Phase IV study to evaluate the effectiveness of additional inhaled sargramostim (GM-CSF) versus standard of care on blood oxygenation in patients with COVID-19 coronavirus infection and acute hypoxic respiratory failure.
- Trial name
- SARPAC (NCT04326920)
- Testing
- Sargramostim, Control
- Where
- 4 sites in Belgium
- Volunteers
- 87 people
- Sponsor
- University Hospital, Ghent
COVID-19, SARS-CoV 2
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
The purpose of this study was to evaluate the efficacy of hydroxychloroquine (HCQ) and azithromycin (Azithro) to prevent hospitalization or death in symptomatic adult outpatients with COVID-19 caused by SARS-CoV-2 infection.
- Trial name
- NCT04358068
- Testing
- Hydroxychloroquine (HCQ), Azithromycin (Azithro)
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Disease (COVID-19)
Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)
This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the percentage of participants who…
- Trial name
- NCT04575597
- Testing
- Molnupiravir
- Where
- 173 sites in United States, Argentina and 21 more
- Volunteers
- 1,735 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
Evaluation of ADG20 for the Prevention of COVID-19
This placebo-controlled study is intended to evaluate ADG20's safety and ability to prevent COVID-19 infection.
- Trial name
- EVADE (NCT04859517)
- Testing
- ADG20
- Where
- 95 sites in United States, Argentina and 7 more
- Volunteers
- 2,582 people
- Sponsor
- Invivyd, Inc.
SARS-CoV 2
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.
- Trial name
- CSSC-004 (NCT04373460)
- Testing
- SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor
- Where
- 29 sites in United States
- Volunteers
- 1,225 people
- Sponsor
- Johns Hopkins University
Pneumonia
Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)
This is a 1:1 ratio, randomized, double-blind, double-dummy, multicenter, global Phase 3 study of tedizolid phosphate (TR-701 FA) 200 mg intravenous (IV) once daily for 7 days versus linezolid (Zyvox®, Zyvoxid®, etc) 600 mg IV…
- Trial name
- NCT02019420
- Testing
- Tedizolid phosphate, Linezolid
- Volunteers
- 726 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
COVID-19, SARS-CoV-2 Infection
Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT04924660)
- Testing
- TXA127, TRV027, Fostamatinib
- Where
- 51 sites in United States
- Volunteers
- 1,060 people
- Sponsor
- Sean Collins
Coronavirus
COVID-19 Convalescent Plasma
The purpose of this study is to assess the feasibility of delivering anti-SARS-CoV-2 convalescent plasma to hospitalized patients with severe or life-threatening COVID-19.
- Trial name
- NCT04340050
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
COVID-19
Safety Study of SLV213 for the Treatment of COVID-19.
This Phase 1 double blind, placebo-controlled study will evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple ascending doses (MAD) of SLV213 in healthy male and female participants, 18-65 years of age.
- Trial name
- NCT06146374
- Testing
- SLV213
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bioavailability
Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
The purpose of this study is to estimate the relative bioavailability of PF-07321332 in different formulations in healthy adult participants.
- Trial name
- NCT05263895
- Testing
- PF-07321332/ritonavir, PF-07321332
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Coronavirus Disease of 2019 (COVID-19) Health Education Initiative for School Safety
The purpose of this study is to compare COVID-19 knowledge, experiences, and health behaviors between participants who received the health initiative and those who did not.
- Trial name
- NCT06938230
- Testing
- Health Education Initiative
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Miami
Bacterial Infections, Intra-Abdominal Infection
Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age
To determine the pharmacokinetic profile and to evaluate the safety and tolerability of ascending multiple doses of tigecycline in patients aged 8 to 11 years with selected serious infections; complicated intra-abdominal…
- Conditions
- Bacterial Infections, Intra-Abdominal Infection, Pneumonia, Bacterial, Skin Diseases, Bacterial
- Trial name
- NCT00488345
- Testing
- Tygacil
- Where
- 36 sites in United States, Belgium and 4 more
- Volunteers
- 59 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
COVID-19
Atovaquone for Treatment of COVID-19
The purpose of the current study is to accelerate the use of a clinically available therapeutic already FDA-approved for other indications in the setting of pandemic COVID-19 addressing a serious and emergent unmet medical need.
- Trial name
- NCT04456153
- Testing
- Experimental Group
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Covid19
Evaluation of Aerosol in a Dental Clinic
The purpose of this study is to evaluate the effectiveness of external evacuation units and mouth rinses during aerosol generating procedures in a dental clinic and to determine the risk level to the dental practitioners during…
- Trial name
- NCT04659928
- Testing
- High volume evacuation (HVE), Extraoral vacuum aspirator (EVA), Hydrogen Peroxide
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.